Fate Therapeutics AI Stock Analysis
Want to see FATE full AI Analyst Report?
Fate Therapeutics (FATE) AI Stock Analysis
Fate Therapeutics
(NASDAQ:FATE)
The score is held down primarily by weak financial performance (ongoing large losses, meaningful cash burn, and a shrinking equity cushion) and a clearly bearish technical setup (price below major moving averages with negative momentum). A positive offset comes from the $15M CIRM grant and related regulatory momentum, but valuation support is limited given negative earnings and no dividend.
Fate Therapeutics (FATE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $122.39M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.50M
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 2.64
- Revenue Growth
- -33.45%
- EPS Growth
- 21.90%
- Country
- US
- Employees
- 161
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Fate Therapeutics Business Overview & Revenue Model
Company Description
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A signifi...
How the Company Makes Money
Fate Therapeutics does not have publicly established, recurring product sales from approved therapies; as a clinical-stage company, its revenue has primarily been generated from collaboration and licensing arrangements rather than commercial product...
Fate Therapeutics Earnings Call Summary
The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.
Q1-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Fate Therapeutics Q1 2024 earnings call, the company provided guidance on its clinical and financial outlook. Key program initiatives were discussed, including the FT819 CAR T-cell and FT522 CAR NK cell programs, with notable translational data presented at the American Society of Gene and Cell Therapy Annual Meeting. The company highlighted its plans to achieve several clinical milestones across its iPSC product pipeline, targeting both cancer and autoimmune diseases. Financially, Fate Therapeutics raised $100 million through an underwritten offering and private placement, ending the first quarter with approximately $391 million in cash. Operating expenses for the full year are projected between $215 million and $230 million, with a year-end cash balance exceeding $270 million. The company's strategic focus is on demonstrating the disease-modifying potential of its therapies while maintaining a strong financial position to support ongoing and future clinical development.
Fate Therapeutics Financial Statement Overview
Summary
Financials remain weak: very small and declining TTM revenue (~$4.8M, down ~27%), large ongoing net losses (~$124M), and substantial cash burn (TTM FCF about -$107M). While losses and burn have improved versus prior years and leverage is not extreme, the continued dependence on external funding and a shrinking equity base materially increase risk.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.75M | 6.65M | 13.63M | 63.53M | 96.30M | 55.85M |
| Gross Profit | -846.00K | -6.25M | -104.90M | -93.65M | 82.54M | 50.00M |
| EBITDA | -114.95M | -127.02M | -176.58M | -142.65M | -267.96M | -206.30M |
| Net Income | -124.43M | -136.31M | -186.26M | -160.93M | -281.72M | -212.15M |
Balance Sheet | ||||||
| Total Assets | 238.28M | 318.94M | 440.69M | 506.22M | 705.56M | 921.46M |
| Cash, Cash Equivalents and Short-Term Investments | 139.13M | 203.66M | 279.07M | 315.18M | 436.23M | 615.91M |
| Total Debt | 74.49M | 77.85M | 85.27M | 103.54M | 109.34M | 114.82M |
| Total Liabilities | 105.24M | 111.75M | 121.97M | 137.80M | 221.62M | 242.62M |
| Stockholders Equity | 133.03M | 207.18M | 318.73M | 368.42M | 483.94M | 678.84M |
Cash Flow | ||||||
| Free Cash Flow | -106.97M | -112.04M | -123.60M | -138.42M | -283.77M | -213.57M |
| Operating Cash Flow | -105.46M | -106.08M | -122.87M | -132.26M | -248.21M | -162.87M |
| Investing Cash Flow | 92.61M | 111.17M | 12.22M | 112.67M | 166.75M | -324.02M |
| Financing Cash Flow | 11.05M | 5.49M | 99.89M | 85.00K | 9.21M | 453.13M |
Fate Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FATE, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 2.07, and below the 200-day MA of 1.98, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 20.91 is Positive, neither overbought nor oversold. The STOCH value of 2.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FATE.
Fate Therapeutics Risk Analysis
Fate Therapeutics disclosed 90 risk factors in its most recent earnings report. Fate Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksFate Therapeutics Peers Comparison
Overall Rating
CGEN73Outperform
ONCY46.6Neutral
CRDF43Neutral
NKTX43Neutral
STTK42Neutral
FATE42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $178.09M | 4.83 | 39.30% | ― | 999.97% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $53.18M | -1.38 | 664.95% | ― | ― | 11.90% | |
| 43Neutral | $69.44M | -1.62 | -111.78% | ― | 11.58% | 32.14% | |
| 43Neutral | $80.31M | -0.65 | -48.58% | ― | ― | -24.79% | |
| 42Neutral | $463.38M | -8.92 | -46.46% | ― | -100.00% | 50.26% | |
| 42Neutral | $122.78M | -0.98 | -73.92% | ― | -33.45% | 21.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics Inc | 1.01 | -0.02 | -1.94% | |
| CGEN | Compugen | 1.88 | 0.35 | 22.88% | |
| ONCY | Oncolytics Biotech | 0.39 | -0.61 | -61.00% | |
| CRDF | Cardiff Oncology, Inc. | 0.89 | -1.14 | -56.06% | |
| NKTX | Nkarta, Inc. | 1.12 | -0.68 | -37.78% | |
| STTK | Shattuck Labs, Inc. | 4.55 | 2.52 | 124.14% |
Fate Therapeutics Corporate Events
Fate Therapeutics Enters $100 Million At-the-Market Sales Agreement
NeutralOn November 5, 2026, Fate Therapeutics entered a sales agreement with Leerink Partners for an at-the-market program allowing it, at its discretion, to sell up to $100 million of common stock. The agreement provides for commissions of up to 3% of gros...
Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial
PositiveOn September 25, 2026, Fate Therapeutics announced that the California Institute for Regenerative Medicine awarded the company a $15 million CLIN2 grant to support RECLAIM-LN, its Phase 2 potentially registrational trial of FT819 in patients with ref...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
